Difference between revisions of "Axitinib (Inlyta)"
Jump to navigation
Jump to search
m (Text replace - "package insert<ref name="insert"></ref>." to "prescribing information.<ref name="insert"></ref>") |
(updated content) |
||
| Line 2: | Line 2: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: Tyrosine kinase inhibitor of multiple receptor tyrosine kinases, including vascular endothelial growth factor receptors VEGFR-1, VEGFR-2, and VEGFR-3, which interferes with tumor angiogenesis, growth, and cancer progression.<ref name="insert">[http://labeling.pfizer.com/ShowLabeling.aspx?id=759 Axitinib (Inlyta) package insert]</ref><ref>[ | + | Class/mechanism: Tyrosine kinase inhibitor of multiple receptor tyrosine kinases, including vascular endothelial growth factor receptors VEGFR-1, VEGFR-2, and VEGFR-3, which interferes with tumor angiogenesis, growth, and cancer progression.<ref name="insert">[http://labeling.pfizer.com/ShowLabeling.aspx?id=759 Axitinib (Inlyta) package insert]</ref><ref>[[Media:Axitinib.pdf | Axitinib (Inlyta) package insert (locally hosted backup)]]</ref><ref>Matthew Stenger. [http://www.ascopost.com/articles/march-15-2012/what-you-need-to-know-about-axitinib/ What You Need to Know About Axitinib, New Agent for Treating Advanced Renal Cell Carcinoma]. ASCO Post, March 15, 2012, Volume 3, Issue 5.</ref> |
<br>Route: PO | <br>Route: PO | ||
<br>Extravasation: n/a | <br>Extravasation: n/a | ||
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> | ||
| + | |||
| + | ==Diseases for which it is used== | ||
| + | *[[Renal cancer]] | ||
| + | *[[Thyroid cancer]] | ||
==Patient drug information== | ==Patient drug information== | ||
| − | *[http://www.inlyta.com/pdf/INLYTA_PatientInformation.pdf Axitinib (Inlyta) patient information (Pfizer)]<ref>[http://www.inlyta.com/pdf/INLYTA_PatientInformation.pdf Axitinib (Inlyta) patient information (Pfizer)]</ref> | + | *[http://www.inlyta.com/pdf/INLYTA_PatientInformation.pdf Axitinib (Inlyta) patient drug information (Pfizer)]<ref>[http://www.inlyta.com/pdf/INLYTA_PatientInformation.pdf Axitinib (Inlyta) patient drug information (Pfizer)]</ref> |
| + | *[http://chemocare.com/chemotherapy/drug-info/axitinib.aspx Axitinib (Inlyta) patient drug information (Chemocare)]<ref>[http://chemocare.com/chemotherapy/drug-info/axitinib.aspx Axitinib (Inlyta) patient drug information (Chemocare)]</ref> | ||
| + | *[http://www.uptodate.com/contents/axitinib-patient-drug-information Axitinib (Inlyta) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/axitinib-patient-drug-information Axitinib (Inlyta) patient drug information (UpToDate)]</ref> | ||
| + | |||
==References== | ==References== | ||
<references/> | <references/> | ||
Revision as of 17:09, 7 October 2012
FDA approved 1/27/2012 Also known as AG013736.
General information
Class/mechanism: Tyrosine kinase inhibitor of multiple receptor tyrosine kinases, including vascular endothelial growth factor receptors VEGFR-1, VEGFR-2, and VEGFR-3, which interferes with tumor angiogenesis, growth, and cancer progression.[1][2][3]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Axitinib (Inlyta) patient drug information (Pfizer)[4]
- Axitinib (Inlyta) patient drug information (Chemocare)[5]
- Axitinib (Inlyta) patient drug information (UpToDate)[6]
References
- ↑ 1.0 1.1 Axitinib (Inlyta) package insert
- ↑ Axitinib (Inlyta) package insert (locally hosted backup)
- ↑ Matthew Stenger. What You Need to Know About Axitinib, New Agent for Treating Advanced Renal Cell Carcinoma. ASCO Post, March 15, 2012, Volume 3, Issue 5.
- ↑ Axitinib (Inlyta) patient drug information (Pfizer)
- ↑ Axitinib (Inlyta) patient drug information (Chemocare)
- ↑ Axitinib (Inlyta) patient drug information (UpToDate)